TLDR Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
Baricitinib, a JAK1/2 inhibitor initially approved for rheumatoid arthritis, has shown efficacy in treating various inflammatory and autoimmune diseases, including COVID-19, systemic lupus erythematosus, psoriasis, atopic dermatitis, and alopecia areata. Clinical trials have demonstrated significant improvements in disease activity and symptoms across these conditions, with notable hair regrowth in alopecia areata patients. However, its use is associated with adverse effects such as infections, liver enzyme dysregulation, and potential malignancies, necessitating careful monitoring and further research to fully understand its safety profile and optimize treatment regimens.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
1 citations
,
August 2021 in “Journal of The American Academy of Dermatology” Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
184 citations
,
February 2015 in “EBioMedicine” A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
3 citations
,
March 2024 in “Journal of Dermatological Treatment” Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
December 2024 in “Clinical and Experimental Dermatology” Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
